Sanne M Zinkstok1, Ludo F Beenen1, Charles B Majoie1, Henk A Marquering1, Rob J de Haan1, Yvo B Roos2. 1. From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands. 2. From the Departments of Neurology (S.M.Z., Y.B.R.), Radiology (L.F.B., C.B.M., H.A.M.), Biomedical Engineering and Physics (H.A.M.), and the Clinical Research Unit (R.J.d.H.), Academic Medical Center University, Amsterdam, The Netherlands. y.b.roos@amc.uva.nl.
Abstract
BACKGROUND AND PURPOSE:Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months. The effect of aspirin on early neurological deterioration (END) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis in Ischemic Stroke (ARTIS) trial. METHODS: END, defined as a ≥4 points National Institutes of Health Stroke Scale worsening ≤24 hours after intravenous thrombolysis, was categorized into SICH (ENDSICH) and cerebral ischemia (ENDCI). Multinomial logistic regression was used to assess the effect of aspirin on END. RESULTS: Of the 640 patients, 31 patients (4.8%) experienced END (14 ENDSICH, 17 ENDCI). Aspirin increased the risk of ENDSICH (odds ratio, 3.73; 95% confidence interval, 1.03-13.49) but not of ENDCI (odds ratio, 1.14; 95% confidence interval, 0.44-3.00). After adjustment for other explanatory variables, the association between aspirin and ENDSICH remained significant. CONCLUSIONS: In this trial, there is no evidence of an early antithrombotic effect from the addition of aspirin to intravenous thrombolysis in acute ischemic stroke.
RCT Entities:
BACKGROUND AND PURPOSE:Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage (SICH), without influencing functional outcome at 3 months. The effect of aspirin on early neurological deterioration (END) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PAThrombolysis in Ischemic Stroke (ARTIS) trial. METHODS: END, defined as a ≥4 points National Institutes of Health Stroke Scale worsening ≤24 hours after intravenous thrombolysis, was categorized into SICH (ENDSICH) and cerebral ischemia (ENDCI). Multinomial logistic regression was used to assess the effect of aspirin on END. RESULTS: Of the 640 patients, 31 patients (4.8%) experienced END (14 ENDSICH, 17 ENDCI). Aspirin increased the risk of ENDSICH (odds ratio, 3.73; 95% confidence interval, 1.03-13.49) but not of ENDCI (odds ratio, 1.14; 95% confidence interval, 0.44-3.00). After adjustment for other explanatory variables, the association between aspirin and ENDSICH remained significant. CONCLUSIONS: In this trial, there is no evidence of an early antithrombotic effect from the addition of aspirin to intravenous thrombolysis in acute ischemic stroke.
Authors: Georgios Tsivgoulis; Aristeidis H Katsanos; Ramin Zand; Vijay K Sharma; Martin Köhrmann; Sotirios Giannopoulos; Efthymios Dardiotis; Anne W Alexandrov; Panayiotis D Mitsias; Peter D Schellinger; Andrei V Alexandrov Journal: J Neurol Date: 2017-05-26 Impact factor: 4.849
Authors: Michael K Schuhmann; Peter Kraft; Michael Bieber; Axel Haarmann; György A Homola; Mirko Pham; Bernhard Nieswandt; Guido Stoll Journal: Transl Stroke Res Date: 2018-01-10 Impact factor: 6.829
Authors: Nirav Dhanesha; Manish Jain; Amit K Tripathi; Prakash Doddapattar; Mehul Chorawala; Girish Bathla; Manasa K Nayak; Madankumar Ghatge; Steven R Lentz; Shigeyuki Kon; Anil K Chauhan Journal: Circ Res Date: 2020-03-20 Impact factor: 17.367
Authors: Hannah J Irvine; Thomas Wk Battey; Ann-Christin Ostwaldt; Bruce Cv Campbell; Stephen M Davis; Geoffrey A Donnan; Kevin N Sheth; W Taylor Kimberly Journal: Int J Stroke Date: 2016-07-09 Impact factor: 5.266